Inhibrx Biosciences Inc.
INBXHealthcare|Biotechnology|US
$84.52
+4.24 (+5.28%)
DCF Value
$0.74
Cash / Share
$8.51
Clinical Trials (7)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT06295731 Ordastobart (INBRX-106) Add-on to Pembrolizumab in 1L HPV+ PD-L1+ R/M OPSCC (HexAgon-HN) | Head and Neck Squamous Cell Carcinoma (HNSCC), HPV Oropharyngeal Squamous Cell Carcinoma (HPV+ OPSCC) | P2P3 | Recruiting | 450 | RCT, Double-blind | INBRX-106, Pembrolizumab |
| NCT04198766 Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist) | Solid Tumor, Non-Small Cell Lung Cancer | P1P2 | Recruiting | 340 | RCT, Single-blind | INBRX-106 - Hexavalent OX40 agonist antibody, pembrolizumab 200 mg, pembrolizumab 400 mg, Carboplatin AUC-5, Carboplatin AUC-6, Pemetrexed 500 mg/m2, Cisplatin 75mg/m2, Paclitaxel 200mg/m2, Nab paclitaxel 100mg/m2, Gemcitabine (1000 mg/m2) |
| NCT04950075 Study of INBRX-109 in Conventional Chondrosarcoma | Conventional Chondrosarcoma | P2 | Active | 206 | RCT, Double-blind | INBRX-109, Placebo |
| NCT06353997 Neoadjuvant INBRX-106 in Combination With Pembrolizumab for Stage II/III TNBC Patients | Triple Negative Breast Cancer | P2 | Recruiting | 12 | Open-label | Pembrolizumab, INBRX-106 |
| NCT03715933 Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas | Ewing Sarcoma, Colorectal Adenocarcinoma | P1 | Recruiting | 411 | Open-label | INBRX-109, Irinotecan, Temozolomide, carboplatin, pemetrexed, Leucovorin, Fluorouracil, Bevacizumab, Trifluridine + Tipiracil |
| NCT03809624 Study of INBRX-105 and INBRX-105 With Pembrolizumab in Patients With Solid Tumors Including Head and Neck Cancer | Metastatic Solid Tumors, Non-small Cell Lung Cancer | P1 | Terminated | 160 | Open-label | INBRX-105 - PDL1x41BB antibody, Pembrolizumab |
| NCT03815396 Phase 1 Study to Assess the Safety, PK and PD of INBRX-101 in Adults With Alpha-1 Antitrypsin Deficiency | Alpha-1 Antitrypsin Deficiency, AATD | P1 | Completed | 31 | Open-label | INBRX-101/rhAAT-Fc |